Validation of the Birmingham Vasculitis Activity Score (BVAS) for use in European multi-centre clinical trials.

Validation of the Birmingham Vasculitis Activity Score (BVAS) for use in European multi-centre clinical trials.

Bibliografske podrobnosti
Main Authors:	Luqmani, R, Bacon, P, Rasmussen, N, Jayne, D
Format:	Journal article
Izdano:	2000

Podobne knjige/članki

Birmingham Vasculitis Activity Score (BVAS) for use in European multi-centre clinical trials
od: Luqmani, R, et al.
Izdano: (2001)

Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
od: Luqmani, R, et al.
Izdano: (1994)

Using the Birmingham vasculitis activity score (BVAS) to screen for vasculitis
od: Mukhtyar, C, et al.
Izdano: (2008)

Using the Birmingham Vasculitis Activity Score (BVAS) for diagnosing vasculitis
od: Luqmani, R, et al.
Izdano: (2009)

Modified Birmingham vasculitis activity score for Wegener's granulomatosis (BVAS/WG) - Construct validity.
od: Maiden, N, et al.
Izdano: (2000)

Modification and validation of the Birmingham Vasculitis Activity Score (version 3).
od: Mukhtyar, C, et al.
Izdano: (2009)

USING THE BIRMINGHAM VASCULITIS ACTIVITY SCORE (VERSION 3) FOR DIAGNOSING VASCULITIS
od: Mukhtyar, C, et al.
Izdano: (2009)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
od: Suppiah, R, et al.
Izdano: (2011)

Validation of the Birmingham Vasculitis Activity Score (Version 3)
od: Mukhtyar, C, et al.
Izdano: (2009)

The prognostic value of BVAS and VDI in ANCA-AAV
od: Suppiah, R, et al.
Izdano: (2011)

Using the Birmingham Vasculitis Activity Score as a Screening Tool in Patients with Suspected Vasculitis
od: Floris, A, et al.
Izdano: (2016)

A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis.
od: Suppiah, R, et al.
Izdano: (2011)

OP0055 Using the Birmingham Vasculitis Activity Score as a screening tool in patients with suspected vasculitis
od: Floris, A, et al.
Izdano: (2016)

Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides.
od: Demirkaya, E, et al.
Izdano: (2012)

A multi-centre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (Cycazarem).
od: Luqmani, R, et al.
Izdano: (1999)

Clinical Predictors of Outcome in Buerger’s Disease using BVAS and DEI.Tak Scoring Systems
od: Prasanta Padhan, et al.
Izdano: (2018-08-01)

Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group.
od: Jayne, DR, et al.
Izdano: (1997)

Clinical Characteristics, Predictors for Mortality and Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score on Survival in ANCA-Associated Vasculitis in Hong Kong
od: Joshua Ka Ho Yeung, et al.
Izdano: (2024-07-01)

European therapeutic trials in ANCA-associated systemic vasculitis: Disease scoring, consensus regimens and proposed clinical trials EUROPEAN COMMUNITY STUDY GROUP ON CLINICAL TRIALS IN SYSTEMIC VASCULITIS ECSYSVASTRIAL (BMHl-Cr93-1078)
od: Rasmussen, N, et al.
Izdano: (1995)

Validation of a new version of the Birmingbam vasculitis activity score
od: Mukhtyar, C, et al.
Izdano: (2008)

VITAL (Vasculitis Integrated Assessment Log) assessment of vasculitis.
od: Bacon, P, et al.
Izdano: (1995)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials.
od: Suppiah, R, et al.
Izdano: (2011)

Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
od: Suppiah, R, et al.
Izdano: (2011)

THE DEMOGRAPHY OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
od: Yew, S, et al.
Izdano: (2012)

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
od: Luqmani, R, et al.
Izdano: (2007)

THE DISEASE CHARACTERISTICS OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
od: Yew, S, et al.
Izdano: (2012)

Development of comprehensive disease assessment in systemic vasculitis.
od: Flossmann, O, et al.
Izdano: (2007)

Development of comprehensive disease assessment in systemic vasculitis.
od: Flossmann, O, et al.
Izdano: (2008)

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
od: Hellmich, B, et al.
Izdano: (2007)

A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).
od: Stone, J, et al.
Izdano: (2001)

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
od: De Groot, K, et al.
Izdano: (2005)

Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus.
od: Mukhtyar, C, et al.
Izdano: (2007)

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in "non-renal" AbCA-associated vasculitis.
od: de Groot, K, et al.
Izdano: (2003)

Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.
od: Exley, A, et al.
Izdano: (1997)

Eular recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis
od: Hellmich, B, et al.
Izdano: (2006)

Treatment of vasculitis in rheumatoid arthritis.
od: Luqmani, R, et al.
Izdano: (1994)

Development of a score for assessment of radiologic damage in large-vessel vasculitis (Combined Arteritis Damage Score, CARDS)
od: Nakagomi, D, et al.
Izdano: (2017)

Vasculitis integrated total assessment log (VITAL): A system for clinical evaluation of vasculitis.
od: Luqmani, R, et al.
Izdano: (1996)

Diagnosis and management of ANCA associated vasculitis.
od: Berden, A, et al.
Izdano: (2012)

Cyclophosphamide and systemic vasculitis.
od: Luqmani, R, et al.
Izdano: (1993)